Table 2. Vaccination Status of Persons Tested for SARS-CoV-2 in England, According to Test Positivity or Negativity and Variant.
| Vaccination Status, Dose, and Interval after Vaccination | Overall (N=2,663,549) |
Test-Negative Status (N=1,572,621) |
Delta Variant (N=204,154) |
Omicron Variant (N=886,774) |
|---|---|---|---|---|
| number (percent) | ||||
| Unvaccinated | 244,716 (9.2) | 107,238 (6.8) | 36,369 (17.8) | 101,109 (11.4) |
| ChAdOx1 nCoV-19 | ||||
| Dose 1 | ||||
| 0–3 wk | 64 (<0.1) | 33 (<0.1) | 8 (<0.1) | 23 (<0.1) |
| ≥4 wk | 16,150 (0.6) | 8,470 (0.5) | 2,133 (1.0) | 5,547 (0.6) |
| Dose 2 | ||||
| 0 or 1 wk | 406 (<0.1) | 224 (<0.1) | 34 (<0.1) | 148 (<0.1) |
| 2–4 wk | 740 (<0.1) | 476 (<0.1) | 28 (<0.1) | 236 (<0.1) |
| 5–9 wk | 1,484 (0.1) | 894 (0.1) | 85 (<0.1) | 505 (0.1) |
| 10–14 wk | 2,700 (0.1) | 1,659 (0.1) | 274 (0.1) | 767 (0.1) |
| 15–19 wk | 17,775 (0.7) | 10,788 (0.7) | 4,013 (2.0) | 2,974 (0.3) |
| 20–24 wk | 120,979 (4.5) | 68,757 (4.4) | 29,100 (14.3) | 23,122 (2.6) |
| ≥25 wk | 292,794 (11.0) | 147,721 (9.4) | 46,103 (22.6) | 98,970 (11.2) |
| Booster dose | ||||
| Any: 0–6 days | 102,033 (3.8) | 54,613 (3.5) | 13,404 (6.6) | 34,016 (3.8) |
| BNT162b2 | ||||
| 1 wk | 60,212 (2.3) | 40,203 (2.6) | 2,088 (1.0) | 17,921 (2.0) |
| 2–4 wk | 165,248 (6.2) | 114,050 (7.3) | 2,029 (1.0) | 49,169 (5.5) |
| 5–9 wk | 157,008 (5.9) | 98,853 (6.3) | 2,291 (1.1) | 55,864 (6.3) |
| ≥10 wk | 34,081 (1.3) | 18,168 (1.2) | 343 (0.2) | 15,570 (1.8) |
| mRNA-1273 | ||||
| 1 wk | 31,958 (1.2) | 22,722 (1.4) | 845 (0.4) | 8,391 (0.9) |
| 2–4 wk | 76,935 (2.9) | 53,353 (3.4) | 417 (0.2) | 23,165 (2.6) |
| 5–9 wk | 22,745 (0.9) | 13,917 (0.9) | 92 (<0.1) | 8,736 (1.0) |
| ≥10 wk | 80 (<0.1) | 38 (<0.1) | 1 (<0.1) | 41 (<0.1) |
| ChAdOx1 nCoV-19 | ||||
| 1 wk | 158 (<0.1) | 107 (<0.1) | 10 (<0.1) | 41 (<0.1) |
| 2–4 wk | 444 (<0.1) | 294 (<0.1) | 19 (<0.1) | 131 (<0.1) |
| 5–9 wk | 440 (<0.1) | 264 (<0.1) | 12 (<0.1) | 164 (<0.1) |
| ≥10 wk | 84 (<0.1) | 48 (<0.1) | 0 | 36 (<0.1) |
| BNT162b2 | ||||
| Dose 1 | ||||
| 0–3 wk | 12,530 (0.5) | 7,038 (0.4) | 944 (0.5) | 4,548 (0.5) |
| ≥4 wk | 54,183 (2.0) | 29,759 (1.9) | 5,381 (2.6) | 19,043 (2.1) |
| Dose 2 | ||||
| 0 or 1 wk | 9,001 (0.3) | 5,900 (0.4) | 466 (0.2) | 2,635 (0.3) |
| 2–4 wk | 13,125 (0.5) | 9,516 (0.6) | 240 (0.1) | 3,369 (0.4) |
| 5–9 wk | 29,912 (1.1) | 20,163 (1.3) | 981 (0.5) | 8,768 (1.0) |
| 10–14 wk | 91,754 (3.4) | 61,014 (3.9) | 5,562 (2.7) | 25,178 (2.8) |
| 15–19 wk | 243,470 (9.1) | 144,172 (9.2) | 17,077 (8.4) | 82,221 (9.3) |
| 20–24 wk | 138,085 (5.2) | 72,018 (4.6) | 10,348 (5.1) | 55,719 (6.3) |
| ≥25 wk | 94,139 (3.5) | 51,625 (3.3) | 8,531 (4.2) | 33,983 (3.8) |
| Booster dose | ||||
| Any: 0–6 days | 80,592 (3.0) | 44,166 (2.8) | 3,212 (1.6) | 33,214 (3.7) |
| BNT162b2 | ||||
| 1 wk | 44,705 (1.7) | 29,459 (1.9) | 631 (0.3) | 14,615 (1.6) |
| 2–4 wk | 87,980 (3.3) | 64,874 (4.1) | 1,220 (0.6) | 21,886 (2.5) |
| 5–9 wk | 156,929 (5.9) | 110,306 (7.0) | 3,769 (1.8) | 42,854 (4.8) |
| ≥10 wk | 104,325 (3.9) | 61,534 (3.9) | 1,222 (0.6) | 41,569 (4.7) |
| mRNA-1273 | ||||
| 1 wk | 18,221 (0.7) | 12,718 (0.8) | 195 (0.1) | 5,308 (0.6) |
| 2–4 wk | 27,480 (1.0) | 20,045 (1.3) | 147 (0.1) | 7,288 (0.8) |
| 5–9 wk | 8,158 (0.3) | 5,311 (0.3) | 40 (<0.1) | 2,807 (0.3) |
| ≥10 wk | 87 (<0.1) | 53 (<0.1) | 1 (<0.1) | 33 (<0.1) |
| mRNA-1273 | ||||
| Dose 1 | ||||
| 0–3 wk | 2,544 (0.1) | 1,429 (0.1) | 134 (0.1) | 981 (0.1) |
| ≥4 wk | 5,656 (0.2) | 3,122 (0.2) | 448 (0.2) | 2,086 (0.2) |
| Dose 2 | ||||
| 0 or 1 wk | 682 (<0.1) | 467 (<0.1) | 35 (<0.1) | 180 (<0.1) |
| 2–4 wk | 1,104 (<0.1) | 855 (0.1) | 13 (<0.1) | 236 (<0.1) |
| 5–9 wk | 3,150 (0.1) | 2,286 (0.1) | 73 (<0.1) | 791 (0.1) |
| 10–14 wk | 14,324 (0.5) | 9,822 (0.6) | 674 (0.3) | 3,828 (0.4) |
| 15–19 wk | 32,913 (1.2) | 20,017 (1.3) | 1,627 (0.8) | 11,269 (1.3) |
| 20–24 wk | 16,291 (0.6) | 8,961 (0.6) | 1,224 (0.6) | 6,106 (0.7) |
| ≥25 wk | 1,221 (<0.1) | 474 (<0.1) | 16 (<0.1) | 731 (0.1) |
| Booster dose | ||||
| Any: 0–6 days | 8,787 (0.3) | 4,745 (0.3) | 203 (0.1) | 3,839 (0.4) |
| BNT162b2 | ||||
| 1 wk | 3,439 (0.1) | 2,031 (0.1) | 15 (<0.1) | 1,393 (0.2) |
| 2–4 wk | 3,410 (0.1) | 2,063 (0.1) | 8 (<0.1) | 1,339 (0.2) |
| 5–9 wk | 36 (<0.1) | 20 (<0.1) | 0 | 16 (<0.1) |
| ≥10 wk | 3 (<0.1) | 0 | 0 | 3 (<0.1) |
| mRNA-1273 | ||||
| 1 wk | 3,001 (0.1) | 1,851 (0.1) | 14 (<0.1) | 1,136 (0.1) |
| 2–4 wk | 3,067 (0.1) | 1,913 (0.1) | 5 (<0.1) | 1,149 (0.1) |
| 5–9 wk | 11 (<0.1) | 4 (<0.1) | 0 | 7 (<0.1) |